Jefferies Starts Gemphire Therapeutics (GEMP) at Buy

August 30, 2016 6:54 AM EDT
Get Alerts GEMP Hot Sheet
Price: $10.20 -1.16%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade GEMP Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies initiates coverage on Gemphire Therapeutics (NASDAQ: GEMP) with a Buy rating and a price target of $15.00.

Analyst Matthew Andrews commented, "Initiating with a Buy Rating and $15 price target. Gemcabene is being developed to address the large, evolving global dyslipidemia market. If gemcabene’s profile and Ph. II(b)/III data replicate Pfizer’s Ph. I/II(a) data, we believe it can ultimately become a broadly-adopted 2nd Line agent used with statins. We estimate 2036 global-adjusted royalties to GEMP of $385M."

For an analyst ratings summary and ratings history on Gemphire Therapeutics click here. For more ratings news on Gemphire Therapeutics click here.

Shares of Gemphire Therapeutics closed at $10.15 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

Jefferies & Co

Add Your Comment